
Novo Nordisk shares drop 6% after updated guidance and Q2 sales report
U.S.-traded shares of Novo Nordisk fell 6% Tuesday after the Danish drugmaker issued updated 2026 guidance and reported second-quarter financial metrics, citing intensifying competition and lower U.S. prices.
